Rapid and noninvasive metabonomic characterization of inflammatory bowel disease - PubMed (original) (raw)
Rapid and noninvasive metabonomic characterization of inflammatory bowel disease
Julian R Marchesi et al. J Proteome Res. 2007 Feb.
Abstract
Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) have a major impact on the health of individuals and populations. Accurate diagnosis of inflammatory bowel disease (IBD) at an early stage, and correct differentiation between Crohn's disease (CD) and ulcerative colitis (UC), is important for optimum treatment and prognosis. We present here the first characterization of fecal extracts obtained from patients with CD and UC by employing a noninvasive metabonomics approach, which combines high resolution 1H NMR spectroscopy and multivariate pattern recognition techniques. The fecal extracts of both CD and UC patients were characterized by reduced levels of butyrate, acetate, methylamine, and trimethylamine in comparison with a control population, suggesting changes in the gut microbial community. Also, elevated quantities of amino acids were present in the feces from both disease groups, implying malabsorption caused by the inflammatory disease or an element of protein losing enteropathy. Metabolic differences in fecal profiles were more marked in the CD group in comparison with the control group, indicating that the inflammation caused by CD is more extensive in comparison with UC and involves the whole intestine. Furthermore, glycerol resonances were a dominant feature of fecal spectra from patients with CD but were present in much lower intensity in the control and UC groups. This work illustrates the potential of metabonomics to generate novel noninvasive diagnostics for gastrointestinal diseases and may further our understanding of disease mechanisms.
Similar articles
- Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Langhorst J, et al. Am J Gastroenterol. 2008 Jan;103(1):162-9. doi: 10.1111/j.1572-0241.2007.01556.x. Epub 2007 Oct 4. Am J Gastroenterol. 2008. PMID: 17916108 - Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; Colitis Foundation of America; Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, Griffiths AM, Jevon GP, Higuchi LM, Hyams JS, Kirschner BS, Kugathasan S, Baldassano RN, Russo PA. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition, et al. J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74. doi: 10.1097/MPG.0b013e31805563f3. J Pediatr Gastroenterol Nutr. 2007. PMID: 17460505 - Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
Vucelic B. Vucelic B. Dig Dis. 2009;27(3):269-77. doi: 10.1159/000228560. Epub 2009 Sep 24. Dig Dis. 2009. PMID: 19786751 Review. - Relationship between fecal lactoferrin and inflammatory bowel disease.
Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Dai J, et al. Scand J Gastroenterol. 2007 Dec;42(12):1440-4. doi: 10.1080/00365520701427094. Scand J Gastroenterol. 2007. PMID: 17852860 - Accuracy of four fecal assays in the diagnosis of colitis.
Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Schoepfer AM, et al. Dis Colon Rectum. 2007 Oct;50(10):1697-706. doi: 10.1007/s10350-007-0303-9. Dis Colon Rectum. 2007. PMID: 17762964 Clinical Trial.
Cited by
- Urine and Serum Metabolomic Profiles Differ by Disease Activity in Pregnant Women With Inflammatory Bowel Diseases.
Wu RY, Tandon P, Oh JS, Ambrosio L, Hotte N, Shah-Gandhi B, Madsen KL, Dieleman LA, Elahi S, Kroeker KI, Huang V. Wu RY, et al. Gastro Hep Adv. 2022 Jul 19;1(6):993-1005. doi: 10.1016/j.gastha.2022.07.008. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39131249 Free PMC article. - Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.
Mestrovic A, Perkovic N, Bozic D, Kumric M, Vilovic M, Bozic J. Mestrovic A, et al. Biomedicines. 2024 Jul 8;12(7):1520. doi: 10.3390/biomedicines12071520. Biomedicines. 2024. PMID: 39062093 Free PMC article. Review. - An integrative multi-omic analysis defines gut microbiota, mycobiota, and metabolic fingerprints in ulcerative colitis patients.
Scanu M, Toto F, Petito V, Masi L, Fidaleo M, Puca P, Baldelli V, Reddel S, Vernocchi P, Pani G, Putignani L, Scaldaferri F, Del Chierico F. Scanu M, et al. Front Cell Infect Microbiol. 2024 May 8;14:1366192. doi: 10.3389/fcimb.2024.1366192. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38779566 Free PMC article. - Emerging role of gut microbiota in autoimmune diseases.
Wang X, Yuan W, Yang C, Wang Z, Zhang J, Xu D, Sun X, Sun W. Wang X, et al. Front Immunol. 2024 May 3;15:1365554. doi: 10.3389/fimmu.2024.1365554. eCollection 2024. Front Immunol. 2024. PMID: 38765017 Free PMC article. Review. - Systematic review of metabolomic alterations in ulcerative colitis: unveiling key metabolic signatures and pathways.
Liu M, Guo S, Wang L. Liu M, et al. Therap Adv Gastroenterol. 2024 Mar 29;17:17562848241239580. doi: 10.1177/17562848241239580. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 38560428 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources